Biora Therapeutics Announces Clinical Trial Results For BT-600

7/1/24 8:01:49 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BIOR alert in real time by email

Drug-device combination leverages Biora's NaviCap™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis

BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform's ability to deliver therapeutics directly to the colon

Drug absorption in colonic tissue extended to distal colon, suggesting pan-colonic delivery

Company to host virtual event with key opinion leaders on July 17

Get the next $BIOR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BIOR

Date	Price Target	Rating	Analyst

More analyst ratings

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The company will not host a conference call. "We've made much faster progress than anticipated developing a smaller BioJet device that is highly desired by pharma companies," said A
11/14/24 8:00:00 AM ET
$BIOR
Biotechnology: Pharmaceutical Preparations
Health Care
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets. Conference Call and Webcast InformationDate: Thursday, November 14, 2024Time: 4:30 PM Eastern time / 1:30 PM Pacific timeConference Call: Domestic 1-877-423-9813International 1-201-689-8573Conference ID 13749254Live Webcast: https://investors.bioratherapeutics.com/events-presentations A replay will
11/7/24 4:30:00 PM ET
$BIOR
Biotechnology: Pharmaceutical Preparations
Health Care
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors supported by BT-600 results and progress toward BioJet™ partnership Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. "Research shows that ulcerative colitis patients with higher drug exposur
8/12/24 4:15:00 PM ET
$BIOR
Biotechnology: Pharmaceutical Preparations
Health Care

$BIOR
Press Releases

Fastest customizable press release news feed in the world

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The company will not host a conference call. "We've made much faster progress than anticipated developing a smaller BioJet device that is highly desired by pharma companies," said A
11/14/24 8:00:00 AM ET
$BIOR
Biotechnology: Pharmaceutical Preparations
Health Care
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets. Conference Call and Webcast InformationDate: Thursday, November 14, 2024Time: 4:30 PM Eastern time / 1:30 PM Pacific timeConference Call: Domestic 1-877-423-9813International 1-201-689-8573Conference ID 13749254Live Webcast: https://investors.bioratherapeutics.com/events-presentations A replay will
11/7/24 4:30:00 PM ET
$BIOR
Biotechnology: Pharmaceutical Preparations
Health Care
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 745,342 shares of the Company's common stock at an offering price of $4.025 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 745,342 shares of common stock. The warrants have an exercise price of $3.90 per share, will be exercisable upon issuance, and will expire five years following issuance. The closing
10/29/24 8:00:00 AM ET
$BIOR
Biotechnology: Pharmaceutical Preparations
Health Care

Biora Therapeutics Announces Clinical Trial Results For BT-600

Chat with this insight

Recent Analyst Ratings for
$BIOR

$BIOR
SEC Filings

SEC Form 8-K filed by Biora Therapeutics Inc.

SEC Form 10-Q filed by Biora Therapeutics Inc.

Biora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$BIOR
Financials

Live finance-specific insights

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

$BIOR
Press Releases

Fastest customizable press release news feed in the world

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

$BIOR
Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $15 Price Target

Biora Therapeutics Announces Presentation Of Supplemental Data From Phase 1 BT-600 Trial; Says 'Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired'